Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Jan 28, 2011

Premium

Integrated Diagnostics announced this week that it has appointed Kenneth Fang chief medical officer and vice president of translational research and clinical development. He will lead the company's efforts for early detection of diseases including lung cancer and Alzheimer's.

Previously Fang was senior director for clinical development at XDx and a faculty member at the University of California at San Francisco. He also co-founded Modus BioMedicine.


Proteome Sciences announced that Alf Lindberg has resigned from its board of directors.


Catherine Derasp this month joined PharmaNet as vice president of clinical operations for the company's Phase I trials, overseeing management of its 350-bed clinical operations in Montreal and Quebec City, Canada.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.